News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.

1Bitget UEX Daily | Fed’s Third-in-Command Signals Steady Policy Stance; SanDisk and Micron Lead AI Sector Gains Amid Divergent US Stocks; PCE Inflation Beats Expectations, Heightening Policy Uncertainty2SPX Blocks Musk's Loss-Making SPCX3 Strategy escapes crisis signal despite heavy hedging, Anchorage says

Crypto market reacts flatly to Powells dovish stance, Bitcoin consolidates below $58,000
Odaily·2024/07/11 02:43
Market Dynamics on July 11: Rebound Nearing its End, Market Awaits CPI Data
Bitget·2024/07/11 02:22

Bitcoin needs to surpass $58,000 to restore bullish trend
Cryptobriefing·2024/07/10 22:55

On the Margin Newsletter: Crypto may seem down, but here’s why analysts remain optimistic
Meanwhile, stocks rally after Jerome Powell finishes his Capitol Hill tour
Blockworks·2024/07/10 21:55
Bitcoin price faces major ‘summer of 2021’ style correction despite BTC whale buying
Cointelegraph·2024/07/10 18:22

Chances of a September rate cut increase for Federal Reserve
Share link:In this post: Jay Powell addresses the Senate with an update on his outlook for the economy. The Fed is scared of making a slightly wrong move, because it could tumble the economy. QCP expects softer CPI figures that would boost the crypto market that has remained surprisingly resilient.Disclaimer. The information provided is not trading advice. Cryptopolitan.com holds no liability for any investments made based on the information provided on this page. We strongly recommend independent research
Cryptopolitan·2024/07/10 17:28

Will Solana (SOL) Experience a Strong Bearish Trend Soon?
Newscrypto·2024/07/10 16:43

Will Avalanche (AVAX) Rebound to $30 This Week?
Newscrypto·2024/07/10 16:43

The bull market will not disappear until you no longer believe that this is a bull market.
Odaily·2024/07/10 14:23

Flash
12:15
Bernstein: The Strength of Data Center REITs Is Underestimated by IndicatorsAccording to Odaily, Bernstein analysts stated in a research report that the strength of data center real estate investment trusts (REITs) is often underestimated. This is because traditional valuation metrics often fail to reflect the long-term value of capital-intensive assets designed to generate cash flow over decades. Adjusted operating cash flow and development return rates, two sector-specific indicators, can more accurately assess this segment’s growth potential. While maintaining shareholder distributions, this sector is able to reinvest funds to expand data center computing power, which is a key advantage. Overall, Bernstein remains optimistic about the outlook for data center REITs. (Golden Ten Data)
12:13
SecondFi: Final Balance Snapshot Completed, Asset Redistribution Expected to Start in Approximately Two WeeksBlockBeats News, June 26th, SecondFi Update on Incident Funds Recovery Progress: The final balance snapshot was taken on June 26th as an accurate record for the subsequent asset recovery. The engineering and security teams have completed balance verification and recovery mechanism evaluation. It is expected that asset returns will begin in approximately two weeks, with about one week for the implementation of the solution and another week for testing and review, with the specific timeline subject to adjustment based on progress.
SecondFi has stated that it will resume operations after confirming the platform's security and completing all security reviews. Currently, users only need to submit an application via a support ticket and are not required to take any other actions.
12:12
Replimune Group Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1 for the treatment of advanced melanoma.This acceptance marks a critical step for the company in advancing the marketing process of this oncolytic virus immunotherapy. The FDA has set the Prescription Drug User Fee Act (PDUFA) target review date as December 25, 2024. The submission of this BLA is primarily based on key CERPASS clinical trial data, which evaluated the efficacy and safety of combining RP1 with the anti-PD-1 therapy librolizumab compared to using librolizumab alone in patients with advanced melanoma.
News
